Dexanabinol

Drug Profile

Dexanabinol

Alternative Names: Dexanabinone; ETS-2101; HU-211; PA-50211; PRS-211007; Sinnabidol

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer e-Therapeutics; Northern Institute for Cancer Research; Pharmos Corporation; University of California, San Diego
  • Class 3-ring heterocyclic compounds; Antineoplastics; Cannabinoids; Neuroprotectants; Small molecules
  • Mechanism of Action Apoptosis stimulants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Brain cancer; Malignant melanoma
  • Discontinued Brain injuries; Glaucoma; Mild cognitive impairment; Multiple sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Brain-cancer(Second-line therapy or greater) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(In volunteers) in United Kingdom (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Second-line therapy or greater) in United Kingdom (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top